{
      "brief_title": [
            "immunogenicity",
            "bridge",
            "investigational",
            "monovalent",
            "vaccine",
            "equivalent",
            "component",
            "gardasil",
            "quadrivalent",
            "vaccine",
            "complete"
      ],
      "brief_summary": [
            "purpose",
            "study",
            "determine",
            "investigational",
            "vaccine",
            "single",
            "component",
            "develop",
            "immune",
            "response",
            "similar",
            "equivalent",
            "investigational",
            "vaccine",
            "four",
            "component",
            "reduce",
            "cervical",
            "disease"
      ],
      "condition": [
            "cancer",
            "wart"
      ],
      "intervention_type": [
            "Biological"
      ],
      "intervention_name": [
            "V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years"
      ],
      "criteria": [
            "inclusion",
            "criterion",
            "female",
            "intact",
            "uterus",
            "lifetime",
            "history",
            "sexual",
            "partner",
            "exclusion",
            "criterion",
            "prior",
            "human",
            "papillomavirus",
            "vaccine",
            "hpv",
            "vaccination",
            "prior",
            "abnormal",
            "pap",
            "prior",
            "history",
            "genital",
            "wart"
      ],
      "gender": "Female",
      "minimum_age": [
            "16",
            "year"
      ],
      "maximum_age": [
            "23",
            "year"
      ],
      "healthy_volunteers": "Accepts Healthy Volunteers",
      "mesh_term": [
            "cervical",
            "neoplasm",
            "acuminata"
      ],
      "id": "NCT00092482"
}